Back to article: Targeting the TGFβ pathway in uterine carcinosarcoma

FIGURE 3: GLT inhibits canonical and non-canonical TGFβ signaling. CS-99 and UMMT-ARK1 cells were grown on a thin layer of Matrigel and treated with TGFβ1, GLT and Cisplatin (CIS, 2.5 µM) as represented, post 24 h of treatment, cell lysate was immunoblotted for (A) canonical and non-canonical markers of TGFβ1 signaling proteins along with Cyclin D1 as a marker for cell cycle progression and Tubulin as the loading control. (B) Effect of TGFβ1 and GLT + TGFβ1 treatment on the EMT markers (FBN – Fibronectin, NCAD – N-cadherin) were evaluated using immunoblotting, GAPDH was used as the loading control.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.